General Inception, Therapeutics Division
A Singular Focus on Immunology
and Inflammation
What we do
The Problem We Are Addressing
While recent clinical successes in immunotherapies are promising, they have also exposed significant challenges highlighting the limitations of such treatments. These include issues with the durability of response, a high proportion of non-responders, and severe, sometimes life-threatening, adverse reactions.
These challenges stem largely from a lack of clear understanding regarding which components of the immune system should be targeted and whether there is a viable pathway for precision drug development.
What we do
Driven by Advancements in Immune Science
Recent breakthroughs utilizing cutting-edge tools like single-cell spatial omics, have significantly deepened our understanding of immune biology. These advances highlight the pivotal role of the innate immune system in driving inflammatory and autoimmune diseases. This insight paves the way for innovative advancements in treatment strategies for chronic inflammation and autoimmunity. Additionally, compelling human genetic evidence has linked specific innate immune sensors to both rare and common immune diseases, offering promising avenues for targeted research and intervention.
This data unveils a vast array of potential drug targets and pathways across various therapeutic areas, providing a more precise approach to addressing
the root causes of diseases.
By leveraging human genetics, we can identify the patients most likely to benefit from specific treatments, heralding a new era of precision immunology.
Leveraging recent discoveries of the innate immune response, and in particular its resolution, may modulate the subsequent development of adaptive immunity, development of drugs that promote or mimic the mode of action of endogenous pro-resolution pathways may afford a novel complementary, or potentially superior, strategy to traditional options. This approach aims not just to suppress inflammation, but to regulate it effectively and restore normal function.
We are only just beginning to unlock the vast potential of the innate immune system, from reducing overactivity in inflammatory disorders to stimulating activity to target cancer.
What we do
Our Collaborative Approach
To propel the next generation of immunotherapies, we must foster a collaborative environment that leverages novel tools and technologies. Our efforts focus on:
Uncovering new insights into immune regulation in inflammation-driven diseases.
Developing modalities for precise drug delivery
Optimizing pharmacological approaches
Implementing strategic clinical development practices
At General Inception, we are committed to developing innovative companies that create first- and best-in-class transformative medicines, which are modality-agnostic and specifically target patients with inflammation-driven diseases and cancer.
What we do
Our Therapeutic Portfolio
Our portfolio includes companies that are
Addressing neuroinflammation by targeting regulated cell death mechanisms
Developing treatments for non-responders and refractory populations to the current standard of care agents in auto-immune diseases such as dupixent, anakinra, and canakinumab
Creating novel small molecule NK cell therapeutics
Addressing immunometabolism in various inflammatory conditions.
Exploring RNA-modifying enzymes, among other cutting-edge approaches.
Enabling Tools and Technologies
In silico drug design (Pharmacelara)
Spatial Omics (Enable Medicine)
General Inception Therapeutics Team
We have brought together a well-connected, highly experienced team with expertise in all stages of drug development from early preclinical through to commercialization of drugs
